JP2022506368A5 - - Google Patents
Info
- Publication number
- JP2022506368A5 JP2022506368A5 JP2021523696A JP2021523696A JP2022506368A5 JP 2022506368 A5 JP2022506368 A5 JP 2022506368A5 JP 2021523696 A JP2021523696 A JP 2021523696A JP 2021523696 A JP2021523696 A JP 2021523696A JP 2022506368 A5 JP2022506368 A5 JP 2022506368A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- human patient
- approximately
- administration
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862756946P | 2018-11-07 | 2018-11-07 | |
| US62/756,946 | 2018-11-07 | ||
| PCT/EP2019/080362 WO2020094698A2 (en) | 2018-11-07 | 2019-11-06 | Compositions and methods for the treatment of estrogen-dependent disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022506368A JP2022506368A (ja) | 2022-01-17 |
| JP2022506368A5 true JP2022506368A5 (https=) | 2022-11-15 |
| JP7459086B2 JP7459086B2 (ja) | 2024-04-01 |
Family
ID=68618113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523696A Active JP7459086B2 (ja) | 2018-11-07 | 2019-11-06 | エストロゲン依存性障害の治療のための組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230067378A1 (https=) |
| EP (1) | EP3876943A2 (https=) |
| JP (1) | JP7459086B2 (https=) |
| KR (1) | KR20210100623A (https=) |
| MA (1) | MA54150A (https=) |
| SG (1) | SG11202104053TA (https=) |
| WO (1) | WO2020094698A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201911598WA (en) | 2017-06-05 | 2020-01-30 | ObsEva SA | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
| SG11201911599XA (en) | 2017-06-05 | 2020-01-30 | ObsEva SA | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss |
| CA3117092A1 (en) | 2018-10-29 | 2020-05-07 | ObsEva S.A. | Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis |
| AU2020325655B2 (en) * | 2019-08-08 | 2025-09-11 | Kissei Pharmaceutical Co., Ltd. | Compositions and methods for the treatment of estrogen-dependent disorders |
| BR112022023937A2 (pt) * | 2020-05-29 | 2022-12-27 | Myovant Sciences Gmbh | Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina |
| CN115232144B (zh) * | 2021-04-22 | 2024-04-02 | 长春金赛药业有限责任公司 | 含氮稠环类衍生物、药物组合物及其制备方法和应用 |
| AU2023325806A1 (en) * | 2022-08-16 | 2025-03-06 | Cms Research & Development Pte. Ltd. | Salt type and crystal form of thienopyrimidinone derivative |
| WO2026060502A1 (pt) * | 2024-09-23 | 2026-03-26 | Klautau Leite Ana Paula | Sistema de diagnóstico por imagem da endometriose profunda e/ou adenomiose e método de análise de exames de imagem |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6960591B2 (en) | 2000-07-05 | 2005-11-01 | Yamanouchi Pharmaceutical Co., Ltd. | Propane-1,3-dione derivative |
| EP1591446B1 (en) | 2003-01-29 | 2013-03-06 | Takeda Pharmaceutical Company Limited | Thienopyrimidine compounds and use thereof |
| AU2004257639B2 (en) | 2003-07-07 | 2011-01-06 | Neurocrine Biosciences, Inc. | Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists |
| PL1939204T6 (pl) | 2005-10-19 | 2024-03-25 | Kissei Pharmaceutical Co., Ltd. | Skondensowana pochodna heterocykliczna, zawierająca ją kompozycja oraz jej zastosowanie medyczne |
| JP5337261B2 (ja) | 2010-02-10 | 2013-11-06 | キッセイ薬品工業株式会社 | 縮合複素環誘導体の塩及びその結晶 |
| WO2014042176A1 (ja) * | 2012-09-14 | 2014-03-20 | キッセイ薬品工業株式会社 | 縮合複素環誘導体の製造方法およびその製造中間体 |
| UA123114C2 (uk) | 2016-08-08 | 2021-02-17 | Кіссеі Фармасьютікал Ко., Лтд. | СПОСІБ ЛІКУВАННЯ ЕНДОМЕТРІОЗУ 3-[2-ФТОР-5-(2,3-ДИФТОР-6-МЕТОКСИБЕНЗИЛОКСИ)-4-МЕТОКСИФЕНІЛ]-2,4-ДІОКСО-1,2,3,4-ТЕТРАГІДРОТІЄНО[3,4-d]ПІРИМІДИН-5-КАРБОНОВОЮ КИСЛОТОЮ |
| SG11201911599XA (en) * | 2017-06-05 | 2020-01-30 | ObsEva SA | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss |
| AU2018419533A1 (en) * | 2018-04-19 | 2020-11-12 | Abbvie Inc. | Methods of treating heavy menstrual bleeding |
-
2019
- 2019-11-06 SG SG11202104053TA patent/SG11202104053TA/en unknown
- 2019-11-06 MA MA054150A patent/MA54150A/fr unknown
- 2019-11-06 WO PCT/EP2019/080362 patent/WO2020094698A2/en not_active Ceased
- 2019-11-06 EP EP19805904.0A patent/EP3876943A2/en active Pending
- 2019-11-06 US US17/291,192 patent/US20230067378A1/en active Pending
- 2019-11-06 KR KR1020217017190A patent/KR20210100623A/ko not_active Withdrawn
- 2019-11-06 JP JP2021523696A patent/JP7459086B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022506368A5 (https=) | ||
| JP2020522571A5 (https=) | ||
| JPH09508418A (ja) | エストロゲン依存症の治療 | |
| KR20090094437A (ko) | 상승-약량 연장 주기 요법을 이용한 호르몬 치료 방법 | |
| JP2020522525A5 (https=) | ||
| JP2021098702A (ja) | 選択的プロゲステロン受容体モジュレーター（ｓｐｒｍ）レジメン | |
| CN1192145A (zh) | 最大限度地减少骨损失的方法 | |
| JP6818047B2 (ja) | ロガニンまたはその誘導体を有効成分として含有する女性更年期症候群の予防、改善または治療用組成物 | |
| JP6691193B2 (ja) | プロゲステロン受容体アンタゴニスト剤形 | |
| EP4009977A2 (en) | Compositions and methods for the treatment of estrogen-dependent disorders | |
| AU2019373349A1 (en) | Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis | |
| KR100232833B1 (ko) | 수정의 방지 또는 억제방법 | |
| JP2006306872A (ja) | 選択的エストロゲン受容体修飾因子及びアロマターゼ阻害剤の組み合わせよりなる医薬組成物及び方法 | |
| TWI835716B (zh) | 治療良性前列腺增殖徵候與症狀之四氫環戊[b]吲哚化合物與磷酸二酯酶抑制劑 | |
| WO2006054938A1 (en) | Gaba-steroid antagonists and their use for the treatment of cns disorders | |
| JP2004520411A5 (https=) | ||
| EP3384913A1 (en) | Selective progesterone receptor modulators and stabilized estrogen level in patient | |
| HK40057959A (en) | Selective progesterone receptor modulator (sprm) regimen | |
| Luu et al. | Obese Women Exhibit Reduced Inhibin B and Estradiol SecretionFollowing Pulsatile Intravenous FSH Administration | |
| HK40010025A (en) | Progesterone receptor antagonist dosage form | |
| HK40059353B (en) | Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis | |
| HK40059353A (en) | Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis | |
| Blackburn | Yale University School of Medicine; and by Blackburn and Cooworkers (11), at the Mayo Clinic. Results of the studies of Thomas et al. | |
| JP2020114805A (ja) | エストロゲン受容体α阻害作用を有するエストロゲン受容体βパーシャルアゴニストを用いた、子宮内膜症、子宮腺筋症等の婦人科疾患の疼痛、及び／又は器質的病変の治療剤 |